Fisons
As of the edition of 20 October 2026, Fisons runs 12 drugs, 12 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 12 |
| Total | 12 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Prednisolone | none listed | 6 |
| Dextromethorphan | none listed | 5 |
| Theophylline anhydrous | none listed | 2 |
| Pseudoephedrine | none listed | 4 |
| Phentermine | none listed | 0 |
| Cromolyn | none listed | 0 |
| Isoproterenol | none listed | 3 |
| Doxepin | none listed | 1 |
| Metolazone | none listed | 1 |
| Iron dextran | none listed | 0 |
| Prednisolone phosphoric acid | none listed | 2 |
| Nedocromil | none listed | 0 |
A route B row is one company at one target.
Where its trials are
- Immune system: 5 trials led
- Infections: 5 trials led
- Lungs and airways: 5 trials led